戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  within OMVs in providing protection against meningococcal infection.
2 e and causes attenuation in a mouse model of meningococcal infection.
3 sposition of properdin-deficient patients to meningococcal infection.
4 e and causes attenuation in a mouse model of meningococcal infection.
5 s released into serum shortly after onset of meningococcal infection.
6 ed in the sera of patients convalescing from meningococcal infection.
7                       No patient developed a meningococcal infection.
8  central nervous system (CNS) in response to meningococcal infection.
9 s the way for a novel therapeutic option for meningococcal infections.
10 ver-represented among patients with systemic meningococcal infections.
11 to treatment-emergent adverse events, and no meningococcal infections.
12  Two patients taking ravulizumab experienced meningococcal infections.
13 ve critical impact on the pathophysiology of meningococcal infections.
14 broad protection against both gonococcal and meningococcal infections.
15 tic lineages caused the majority of invasive meningococcal infections.
16                Of 228 patients with invasive meningococcal infection, 67 were aged 16 to 30 years; 11
17             Given the increased incidence of meningococcal infection among adolescents and the substa
18 important in understanding human immunity to meningococcal infections and can aid in the design of an
19 ably contributes to the early containment of meningococcal infection, and sensing defects create incr
20 before and during an outbreak of serogroup C meningococcal infection at a university in the United Ki
21 deficient patients are susceptible to lethal meningococcal infection, but the mechanism of this selec
22  growing trend in the proportion of invasive meningococcal infections caused by serogroup Y.
23 n meningitis belt has eliminated serogroup A meningococcal infections for >300 million Africans.
24 se-control study of US college students with meningococcal infection from September 1, 1998, to Augus
25  encapsulated bacterial infections including meningococcal infections, hypersensitivity, or thromboem
26                                 Incidence of meningococcal infection in 15 through 24 year olds in Ma
27                             The incidence of meningococcal infection in college students is similar t
28 es have documented the incidence of invasive meningococcal infection in college students or whether t
29 ave shown promise for enhancing detection of meningococcal infection in selected scenarios.
30                                  The rate of meningococcal infection in the treated cohort was 550 ti
31                        No deaths or cases of meningococcal infection occurred during the study.
32     No unexpected adverse events, deaths, or meningococcal infections occurred.
33                                              Meningococcal infection remains a worldwide health probl
34  infection-related adverse events, including meningococcal infections, were observed through the exte